<DOC>
	<DOC>NCT00876044</DOC>
	<brief_summary>The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters, clinical safety and pharmakokinetic (PK) parameters.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients</brief_title>
	<detailed_description>All patients receive background treatment with docetaxel.</detailed_description>
	<criteria>Inclusion criteria: Solid malignancy, documented by pathologic report, for which treatment with singleagent docetaxel (administered every 3 weeks, at dose &lt;75 mg/m2)is planned. Written informed consent Exclusion criteria: Patient has received more than 2 prior lines of cytotoxiccontaining chemotherapy Conditions with screening ECG repolarization difficult to interpret, or showing significant abnormalities. This includes, but is not limited to: high degree AV block, pacemaker, atrial fibrillation or flutter QTcF &gt;480 msec on screening ECG The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>